Published in J Pediatr on November 01, 2006
HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog (2012) 1.70
HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J Virol (2011) 1.15
Immunology of pediatric HIV infection. Immunol Rev (2013) 1.02
The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies. Curr HIV Res (2009) 0.97
Human milk oligosaccharide concentration and risk of postnatal transmission of HIV through breastfeeding. Am J Clin Nutr (2012) 0.96
Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. J Virol (2013) 0.95
Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J Immunol (2010) 0.92
High cell-free virus load and robust autologous humoral immune responses in breast milk of simian immunodeficiency virus-infected african green monkeys. J Virol (2011) 0.90
Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. J Virol (2015) 0.89
Are anti-HIV IgAs good guys or bad guys? Retrovirology (2014) 0.83
The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context? Retrovirology (2013) 0.82
Systemic and mucosal differences in HIV burden, immune, and therapeutic responses. J Acquir Immune Defic Syndr (2011) 0.81
Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. J Virol (2013) 0.81
Maternal cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus transmission in very low-birth-weight preterm infants. J Infect Dis (2011) 0.80
Adaptive HIV-specific B cell-derived humoral immune defenses of the intestinal mucosa in children exposed to HIV via breast-feeding. PLoS One (2013) 0.79
The oral mucosa immune environment and oral transmission of HIV/SIV. Immunol Rev (2013) 0.79
Transfer of Maternal Antimicrobial Immunity to HIV-Exposed Uninfected Newborns. Front Immunol (2016) 0.78
Maternal milk IgA and mother-to-child transmission of human immunodeficiency virus: not a silver spoon. J Pediatr (2006) 0.76
Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women. PLoS One (2015) 0.75
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
Issues in the design of a clinical trial with a behavioral intervention--the Zambia exclusive breast-feeding study. Control Clin Trials (2004) 2.36
Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med (1992) 2.33
Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS (2000) 2.26
Infective and anti-infective properties of breastmilk from HIV-1-infected women. Lancet (1993) 2.18
Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis (2003) 2.10
HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS (1999) 1.89
Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis (1999) 1.88
The immune system of human milk: antimicrobial, antiinflammatory and immunomodulating properties. Pediatr Infect Dis J (1993) 1.87
Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis (1998) 1.74
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS (2000) 1.66
Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. J Infect Dis (1999) 1.54
Cell-free virus in breast milk of HIV-1-seropositive women. J Acquir Immune Defic Syndr (2000) 1.50
Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr (2002) 1.45
Quantitation of human immunodeficiency virus type 1 in breast milk. J Clin Microbiol (2003) 1.42
Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis (1995) 1.40
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34
Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett (2001) 1.31
Elevated IgA concentration in milk produced by mothers delivered of preterm infants. J Pediatr (1981) 1.22
Breast milk and HIV-1: vector of transmission or vehicle of protection? Lancet Infect Dis (2003) 1.20
Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis (2001) 1.20
Human milk protection against infectious diarrhea: implications for prevention and clinical care. Semin Pediatr Infect Dis (2004) 1.19
Human immunodeficiency virus-specific CD8(+) T cells in human breast milk. J Virol (2002) 1.19
Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS (2001) 1.16
Cytokines in breast milk from allergic and nonallergic mothers. Pediatr Res (2000) 1.15
Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS (2003) 1.13
Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr (2005) 1.12
Mastitis and immunological factors in breast milk of lactating women in Malawi. Clin Diagn Lab Immunol (1999) 1.12
Inactivation of human immunodeficiency virus type I in human milk: effects of intrinsic factors in human milk and of pasteurization. J Hum Lact (1993) 1.11
High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retroviruses (1997) 1.10
Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS (2002) 1.09
Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis (2000) 1.08
Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information. J Infect Dis (1997) 1.07
A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J Immunol (2001) 1.07
A human milk factor inhibits binding of human immunodeficiency virus to the CD4 receptor. Pediatr Res (1992) 1.05
Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women. J Hum Lact (1999) 1.01
HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. J Biol Regul Homeost Agents (2000) 0.97
Human milk glycosaminoglycans inhibit HIV glycoprotein gp120 binding to its host cell CD4 receptor. J Nutr (1995) 0.94
Modulation of human immunodeficiency virus type 1 infection of human monocytes by IgA. J Infect Dis (1995) 0.94
Human immunodeficiency virus type 1 IgA antibody in breast milk and serum. Pediatr Infect Dis J (1994) 0.92
Secretory leukocyte protease inhibitor in colostrum and breast milk is not a major determinant of the protection of early postnatal transmission of HIV. AIDS (1999) 0.92
Mother-to-child transmission of HIV-1: the 'all mucosal' hypothesis as a predominant mechanism of transmission. AIDS (1999) 0.92
Prevalence and magnitude of human immunodeficiency virus (HIV) type 1-specific lymphocyte responses in breast milk from HIV-1-seropositive women. J Infect Dis (2003) 0.87
Antibodies to human immunodeficiency virus in the breast milk of healthy, seropositive women. Pediatrics (1990) 0.84
Human immunodeficiency virus antibodies of IgG, IgA, and IgM subclasses in milk of seropositive mothers. J Pediatr (1988) 0.83
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA (2006) 17.93
Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA (2007) 7.00
Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med (2008) 6.80
Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS (2003) 4.82
Exclusive breastfeeding promotion by peer counsellors in sub-Saharan Africa (PROMISE-EBF): a cluster-randomised trial. Lancet (2011) 3.21
Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events. AIDS (2005) 3.15
A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia. J Acquir Immune Defic Syndr (2008) 3.04
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS (2005) 2.97
Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. J Acquir Immune Defic Syndr (2003) 2.97
Promotion of couples' voluntary counselling and testing for HIV through influential networks in two African capital cities. BMC Public Health (2007) 2.55
Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. J Virol (2002) 2.38
Issues in the design of a clinical trial with a behavioral intervention--the Zambia exclusive breast-feeding study. Control Clin Trials (2004) 2.36
Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? Clin Infect Dis (2005) 2.32
Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol (2003) 2.20
Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS (2007) 2.19
Barriers to acceptance and adherence of antiretroviral therapy in urban Zambian women: a qualitative study. AIDS Care (2009) 2.18
Evolution of couples' voluntary counseling and testing for HIV in Lusaka, Zambia. J Acquir Immune Defic Syndr (2008) 2.17
B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood (2002) 2.17
A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol (2007) 2.17
Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. J Clin Gastroenterol (2012) 2.15
The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS (2009) 2.15
Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts. J Infect Dis (2006) 2.05
Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania. Pediatr Infect Dis J (2008) 2.00
Parasites represent a major selective force for interleukin genes and shape the genetic predisposition to autoimmune conditions. J Exp Med (2009) 2.00
A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS (2006) 1.96
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Postnatal human herpesvirus 8 and human immunodeficiency virus type 1 infection in mothers and infants from Zambia. J Infect Dis (2003) 1.74
Growth faltering due to breastfeeding cessation in uninfected children born to HIV-infected mothers in Zambia. Am J Clin Nutr (2009) 1.73
Traditional practices and exposure to bodily fluids in Lusaka, Zambia. Trop Med Int Health (2007) 1.71
Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission. J Acquir Immune Defic Syndr (2006) 1.71
Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-infected mothers. Clin Infect Dis (2010) 1.70
Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission. Am J Obstet Gynecol (2006) 1.69
Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to- child HIV transmission. AIDS (2010) 1.64
High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission. PLoS One (2007) 1.62
The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis (2007) 1.61
Profile of the circulating DNA in apparently healthy individuals. Clin Chem (2009) 1.61
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol (2007) 1.60
Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies. Am J Public Health (2002) 1.56
'No sister, the breast alone is not enough for my baby' a qualitative assessment of potentials and barriers in the promotion of exclusive breastfeeding in southern Zambia. Int Breastfeed J (2008) 1.56
Use of traditional medicine among pregnant women in Lusaka, Zambia. J Altern Complement Med (2007) 1.55
Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study. J Int AIDS Soc (2010) 1.54
Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis (2002) 1.52
Violence and abuse among HIV-infected women and their children in Zambia: a qualitative study. J Nerv Ment Dis (2006) 1.48
Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr (2002) 1.45
Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood (2011) 1.42
Distinct cytokine patterns associated with different forms of chronic dysimmune neuropathy. Muscle Nerve (2010) 1.41
Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis (2011) 1.41
Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr (2009) 1.40
Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS (2006) 1.40
HLA allele sharing and HIV type 1 viremia in seroconverting Zambians with known transmitting partners. AIDS Res Hum Retroviruses (2004) 1.37
The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol (2006) 1.37
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS (2008) 1.36
Prolonged breast-feeding and mortality up to two years post-partum among HIV-positive women in Zambia. AIDS (2005) 1.36
IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol (2007) 1.35
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis (2007) 1.33
Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1. Lancet (2003) 1.31
Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J (2010) 1.31
Do targeted HIV programs improve overall care for pregnant women?: Antenatal syphilis management in Zambia before and after implementation of prevention of mother-to-child HIV transmission programs. J Acquir Immune Defic Syndr (2008) 1.29
Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS (2013) 1.29
PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol (2008) 1.28
Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS (2010) 1.26
Early weaning increases diarrhea morbidity and mortality among uninfected children born to HIV-infected mothers in Zambia. J Infect Dis (2011) 1.26
Declining HIV prevalence among young pregnant women in Lusaka, Zambia. Bull World Health Organ (2008) 1.26
CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. AIDS (2005) 1.26
Differential effects of early weaning for HIV-free survival of children born to HIV-infected mothers by severity of maternal disease. PLoS One (2009) 1.25
Expanded services for the prevention of mother-to-child HIV transmission: field acceptability of a pilot program in Lusaka, Zambia. J Acquir Immune Defic Syndr (2007) 1.23
Detection of mucosal antibodies in HIV type 1-infected individuals. AIDS Res Hum Retroviruses (2002) 1.21
Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. Antivir Ther (2009) 1.20